

Article

Combination of Policosanol (Raydel[®]) and Atorvastatin Improve High-Density Lipoproteins and Antioxidant Abilities to Protect Vital Organs and Fertility in Hyperlipidemic/Hyperglycemic Zebrafish

Kyung-Hyun Cho * , Ashutosh Bahuguna, Ji-Eun Kim, Sang Hyuk Lee, Yunki Lee, Cheolmin Jeon, Seung Hee Baek and Krismala Djayanti

Raydel HDL Research Institute, Medical Innovation Complex, Daegu 41061, Republic of Korea

* Correspondence: chok@raydel.co.kr; Tel.: +82-53-964-1990; Fax: +82-53-965-1992

Abstract

Objectives: The study explores the comparative effects of atorvastatin (ATV), policosanol (PCO), and their combination (ATV+PCO) on metabolic stress and associated organ damage in hyperlipidemic–hyperglycemic zebrafish. **Methodology:** Hyperlipidemic–hyperglycemic zebrafish ($n = 112$) were segregated into four groups ($n = 28$ /group) and fed either with a high-cholesterol (HC, 4% w/w) and a high-galactose (HG, 30% w/w) diet, HCHG diet with policosanol (PCO, 0.1% w/w), atorvastatin (ATV, 0.1% w/w), or ATV+PCO (0.1% w/w each). After 12 weeks of supplementation, survivability and embryo production were assessed, along with biochemical and histological examinations of various organs across the groups. **Results:** Following a 12-week dietary regime, compromised zebrafish survival probability (0.75) was observed in the ATV group, compared to the PCO group (0.89), which increased to 0.82 with combined intake of ATV+PCO. A significantly greater effect of ATV than PCO was observed in reducing the HCHG elevated TC, TG, and LDL-C levels. However, compared to the ATV, a significantly higher HDL-C/TC (%) ratio was spotted in the PCO. Unlike individual supplementation (ATV or PCO), a combined intake (ATV+PCO) proved highly effective in counteracting dyslipidemia, especially by augmenting the HDL-C/TC (%) ratio. Interestingly, no protective effect of ATV was observed against elevated blood glucose levels, oxidative stress, or diminished antioxidant markers. Whereas ATV, in combination with PCO, significantly reduced blood glucose and MDA levels and elevated sulfhydryl content and antioxidant variables (ferric iron reduction ability and paraoxonase activity). ATV+PCO supplementation effectively mitigated HCHG-induced fatty liver, inflammation, ROS generation in the kidney, and brain senescence. Likewise, ATV+PCO improved reproductive health, elevating spermatozoa counts and embryo production ability of zebrafish. Notably, ATV+PCO supplementation significantly inhibited the HCHG-induced eye damage and demyelination in the retina, while ATV alone failed to establish any such changes. **Conclusions:** The study indicates the combinational therapy of ATV+PCO may offer a possible treatment to counter the metabolic stress and associated events in hyperlipidemic–hyperglycemic zebrafish.

Keywords: atorvastatin; embryos; infertility; myelin; oxidative stress; policosanol; senescence



Academic Editors: Réjean Couture and Yanka Karamalakova

Received: 10 December 2025

Revised: 31 December 2025

Accepted: 28 January 2026

Published: 29 January 2026

Copyright: © 2026 by the authors.

Licensee MDPI, Basel, Switzerland.

This article is an open access article distributed under the terms and

conditions of the [Creative Commons](https://creativecommons.org/licenses/by/4.0/)

[Attribution \(CC BY\)](https://creativecommons.org/licenses/by/4.0/) license.

1. Introduction

Dyslipidemia refers to an abnormal metabolic condition characterized by elevated concentrations of plasma total cholesterol, triglycerides, and low-density lipoprotein cholesterol (LDL-C), along with decreased levels of high-density lipoprotein cholesterol (HDL-C) or hypoalphalipoproteinemia [1]. A firm association of dyslipidemia with cardiovascular diseases is well established. In addition, dyslipidemia has been shown to impair the function of various organs, including the kidney, liver, ovaries, and testis. Recent reports depicted nearly one in three adults suffering from hypercholesterolemia, raising serious global concerns due to its contribution to coronary and cerebrovascular events [1].

To counter dyslipidemia, various classes of drugs, including statins, niacin, ezetimibe, fibrates, bile acid sequestrants, and PCSK9 inhibitors, are utilized [2]. Nevertheless, statins are the most common and first-line lipid-lowering medications. Among the statins, atorvastatin (ATV) is the most frequently prescribed, which competitively inhibits 3-hydroxy-3-methylglutarylcoenzyme A (HMG-CoA) reductase, a rate-limiting enzyme in cholesterol biosynthesis [3]. Despite the lipid-lowering effects, prolonged statin consumption displayed a variety of side effects, including toxicity to the liver [4,5], kidney [6], brain [5], and, most concerning, myotoxicity [7]. In muscle, statins impair mitochondrial function, inhibit the biogenesis of coenzyme Q₁₀ (CoQ₁₀) and ATP, provoke reactive oxygen species (ROS) generation, and disrupt calcium homeostasis, leading to muscle disorders such as myalgia and rhabdomyolysis [8–10]. In addition, ATV has shown a notable impact on male fertility, testicular function, and sperm parameters, adversely influencing testicular morphology by altering seminiferous tubules diameter, increasing interstitial space, elevating sperm mortality, and decreasing cellular antioxidant activity [11]. Growing evidence affirms a possible connection between statin use and a greater risk of type 2 diabetes [12–14]. Several clinical studies have confirmed that ATV can impair insulin sensitivity and secretion, consequently elevated Homeostatic Model Assessment (HOMA) indices, indicating a higher likelihood of diabetes development [15–17].

Considering the adverse effects of statins, an alternative herbal therapy is gaining popularity. Even the International Lipid Expert Panel has recommended plant-derived monomers and their derivatives as a safe and well-tolerated option, prompting them as potential alternatives to statins, particularly for individuals who cannot tolerate statin therapy [18]. A variety of herbal preparations, including red yeast rice extract, policosanols, phytoestrogens, and phytosterols, demonstrated promising results in managing dyslipidemia [19]. Particularly, policosanol, which is a blend of long-chain aliphatic alcohol (LCAA) that can be obtained from certain plants and insect sources, has attracted significant attention for managing dyslipidemia [20]. In clinical studies, it has been confirmed that policosanols facilitates cholesterol efflux [21] and substantially improves HDL quality and quantity [22]. However, the source material origin, type of source material, and extraction method have a significant impact on policosanol composition and, in turn, its functionality. For example, policosanols derived from wax of Cuban sugarcane (*Saccharum officinarum* L.) consists of a unique mixture of eight LCAA that is widely acclaimed for its distinct functionality compared to other policosanols. Beyond the proven effect on dyslipidemia, studies have deciphered policosanol's functionality to lower blood pressure [23,24] and blood glucose levels [25]. In addition, policosanol acts as an anti-platelet aggregation agent [20] and inhibits LDL oxidation and glycation of lipoproteins [26]. In a recent clinical study, policosanol intake with exercise improved HDL functionality and antioxidant status without affecting CoQ₁₀ metabolism or liver toxicity [22]. In a wide array of animal studies (rats, dogs, and monkeys) policosanol proved safe without any sign of toxicity [27]. Consistently, in a post-marketing survey with over 2500 individuals, policosanol was found

to be safe, though some participants (0.07%) reported minor polyurea, weight loss, and polyphagia [27].

Although several studies have investigated either policosanol or statins individually, a comparative evaluation of the two, particularly their combined use, remains limited [28–30]. Importantly, most comparative studies focused mainly on dyslipidemia and did not examine its impact on various organs [28–30]. In this viewpoint, the present study was designed to comprehensively evaluate the effects of policosanol (PCO), atorvastatin (ATV), and their combination (ATV+PCO) against high-cholesterol- and high-galactose-induced diet metabolic disturbance, oxidative stress, and damage to multiple organs (including the liver, kidney, brain, testis, ovaries, and eyes) in zebrafish.

Zebrafish was chosen as an experimental animal based on its suitability as preclinical research model for human kidney [31], liver [32], and reproductive diseases [33]. In addition, under a high-cholesterol diet (HCD), many of the events in zebrafish resemble human hepatic steatosis and are comparable to the gene expression pattern observed in the mammalian model [34]. Also, HCD-induced responses in zebrafish are parallel to many human pathophysiological conditions, including macrophage lipid accumulation and vascular lesion formation [34]. Most importantly, zebrafish harbor many lipid-metabolism proteins, receptors, and enzymes analogous to those in humans, including cholesteryl ester transfer protein (CETP), a critical determinant of human lipid metabolism (to lower HDL-C), that is absent in mice [35], favoring zebrafish as a suitable model for lipoprotein research [35,36]. Consequently, the results from zebrafish studies can provide important mechanistic insights and biological understanding that may help to design human studies.

2. Results

2.1. Survivability and Body Weight Analysis

The Kaplan–Meier survival probability curve depicts a substantial survival difference (log-rank $\chi^2 = 14.2$, $p < 0.01$) across the groups. As depicted in Figure 1A, the survivability of zebrafish declines with the time in the HCHG consumed group. Up to week 3, the utmost survival probability (1.0) was observed in the HCHG group, which fell to 0.96 at week 4 and further to 0.71 and 0.61 at week 8 and week 12, respectively. In contrast, the absolute survival probability (1.0) up to week 8 was noticed in the ND group, which declined slightly to 0.96 at week 12. Supplementation of PCO with HCHG demonstrates a protective effect against HCHG-induced zebrafish mortality, with 0.89 survival probability at week 12, which is ~1.5-fold more than the survival probability of in the HCHG group (0.61, week 12). In contrast, the ATV-supplemented group showed a survival probability of 0.75 at week 12, which was ~1.2 times lower than that observed in the PCO-consumed group. The intake of ATV with PCO (i.e., ATV+PCO) effectively increased survival probability (0.82 at week 12), compromised by HCHG consumption. Compared with the ATV and HCHG groups, the ATV+PCO co-supplemented group showed higher survivability at week 12.

Among all groups, a significant ($p < 0.001$) change in body weight compared to week 0 was observed after 12 weeks of intake of the designated diets (Figure 1B). At week 12, the highest body weight was spotted in the HCHG group (512.9 mg), which was notably 11.2%, 4.6%, and 9.7% more than the 12-week body weight of zebrafish in the PCO (455.4 mg), ATV (489.5 mg), and ATV+PCO (462.8 mg) supplemented groups, respectively; however, statistically non-significant relationship in the body weights was detected between the groups.




Figure 1. Zebrafish survivability and body weight over 12 weeks of intake of different diets. (A) Kaplan–Meier survival probability curve. The symbols ** represent the statistical difference at $p < 0.01$ (log-rank $\chi^2 = 14.2$). (B) Zebrafish body weight at week 0 and at week 12, after intake of specified diets. ND, HC, HG, PCO, and ATV are abbreviations for normal diet, high cholesterol, high galactose, policosanols, and atorvastatin, respectively. The *** signifies a statistical significance ($p < 0.001$) between the body weight of week 0 and week 12 in the same group, while †† depicts a statistical difference ($p < 0.01$) vs. HCHG group final day body weight; “ns” represent non-significant difference ($p > 0.05$).

2.2. Organ Weight and Morphology Analysis

The liver (whole organ) analysis revealed hepatomegaly, with 1.9 times more liver weight in the HCHG-consuming group relative to the ND group (Figure 2A,B). Supplementation with PCO effectively prevented hepatomegaly, with liver weight reduced by 1.6-fold compared to the HCHG group. No substantial effect of ATV supplementation was observed on preventing HCHG-induced hepatomegaly or liver weight. In contrast, when ATV is co-supplemented with PCO (ATV+PCO), it effectively minimizes the HCHG-induced hepatomegaly and liver weight.

The kidney morphology analysis revealed nephromegaly and elevated kidney weight in the HCHG group, which was substantially inhibited by PCO supplementation (Figure 2A,C). Unlike this, ATV alone and in combination with PCO (i.e., ATV+PCO) failed to show a significant impact on the prevention of HCHG-triggered nephromegaly and kidney weight.

Compared to the ND (control) group, HCHG intake for 12 weeks substantially altered the morphology and weight of the brain, testis, and ovary (Figure 2A,D–F). Interestingly, a non-significant ($p > 0.05$) impact of PCO, ATV, and ATV+PCO was noticed on the organ weight (brain, ovary, and testis) disturbed by the supplementation of HCHG.

2.3. Blood Lipoprotein Profile and Glucose Level

Relative to the baseline values observed in the ND group, the total cholesterol (TC), triglycerides (TG), and low-density lipoprotein cholesterol (LDL-C) levels were significantly elevated by 2.8-fold, 2.7-fold, and 11.9-fold, respectively, after 12 weeks of intake of HCHG (Figure 3A–C). Supplementation with both PCO and ATV significantly reduced elevated TC levels by 1.2- and 1.6-fold, TG levels by 1.3- and 1.4-fold, and LDL-C levels by 1.5- and 2.1-fold, respectively. Relative to PCO, ATV proved ~23%, 8%, and 29% more efficient in reducing elevated TC, TG, and LDL-C levels, respectively. Notably, the ATV+PCO combination proved significantly more effective than ATV or PCO alone in minimizing TC, TG, and LDL-C levels.




Figure 2. Zebrafish (A) organ morphology and organ weight of (B) liver, (C) kidney, (D) brain, (E) testis, and (F) ovary after 12 weeks of intake of specified diets. ND, HC, HG, PCO, and ATV are abbreviations for normal diet, high cholesterol, high galactose, policosanols, and atorvastatin, respectively. The signs *, **, and *** highlight statistical significance at $p < 0.05$, $p < 0.01$, and $p < 0.001$, respectively, vs. HCHG groups. The † and †† depict a statistical significance at $p < 0.05$ and $p < 0.01$ compared to the ATV group. “ns” represents a non-significant difference ($p > 0.05$).

HDL-C levels were significantly reduced by 1.9-fold following HCHG intake compared with the ND group (Figure 3D). Compared to the HCHG group, supplementation of PCO and ATV+PCO significantly enhanced the HDL-C concentration by 1.6-fold and 1.3-fold, respectively. Consistently, supplementation with PCO and ATV+PCO significantly increased the HCHG disturbed HDL-C/TC ratio by 1.9-fold and 2.4-fold, respectively (Figure 3E). Only ATV supplementation did not substantially elevate HDL-C level; yet it significantly ($p < 0.05$) augmented the HDL-C/TC ratio.

The basic blood glucose level (68.5 mg/dL) was significantly 38.2% ($p < 0.001$) elevated by the consumption of the HCHG diet (94.8 mg/dL), which was substantially lowered by 23.2% by the intake of PCO (Figure 3F). Unlike PCO, a non-significant effect of ATV consumption was noticed on the reduction in the HCHG-elevated blood glucose level. However, when ATV was combined with PCO (i.e., ATV+PCO), a 16% reduction in glucose levels was detected relative to the HCHG group.




Figure 3. A comparative quantification of the plasma lipoprotein profile and glucose level in zebrafish after 12 weeks intake of the specified diets. (A) Total cholesterol (TC), (B) triglycerides (TG), (C) low-density lipoprotein cholesterol (LDL-C), (D) high-density lipoprotein cholesterol (HDL-C), (E) % ratio of HDL-C/TC, and (F) glucose levels. ND, HC, HG, PCO, and ATV are abbreviations for normal diet, high cholesterol, high galactose, policosanols, and atorvastatin, respectively. The signs *, **, and *** highlight statistical significance at $p < 0.05$, $p < 0.01$, and $p < 0.001$, respectively, vs. HCHG groups. The †, ††, and ††† depict a statistical significance at $p < 0.05$, $p < 0.01$, and $p < 0.001$ compared to the ATV group. The § and §§§ depict a statistical significance at $p < 0.05$ and $p < 0.001$ compared to the PCO group. “ns” represent a non-significant difference ($p > 0.05$).

2.4. Plasma Analysis of Malondialdehyde, Antioxidant Variables, and Liver Biomarkers

An elevated blood malondialdehyde (MDA) level (13.8 μM) was observed in the HCHG group, which was 2.5 times more than the MDA level (5.5 μM) of the ND (control) group (Figure 4A). Supplementation with PCO significantly (1.8-fold) inhibited the HCHG-elevated MDA level. In contrast, no effect of ATV was observed on the reduction in MDA level. However, ATV in combination with PCO (i.e., ATV+PCO) effectively lowers the HCHG heightened MDA level by 1.6-fold.

A reduced level of sulfhydryl content (8.1 nmol/mg) (Figure 4B) and paraoxonase (PON) activity (3.1 IU/L/min) (Figure 4C) was observed in the HCHG-supplemented group, which was substantially 1.5-fold to 1.4-fold and 2.3-fold to 1.6-fold enhanced by the intake of PCO and ATV+PCO, respectively. Nevertheless, ATV alone did not have a significant effect on HCHG-disturbed sulfhydryl content or PON activity. The plasma ferric ion reduction ability (FRA) was substantially reduced (193.4 μM) by the consumption of HCHG, which was significantly enhanced up to 345.4 μM , 235.4 μM , and 270.9 μM by the consumption of PCO, ATV, and ATV+PCO, respectively (Figure 4D). Similarly, the plasma basal level (ND group) of aspartate aminotransferase (AST, 337.7 IU/L) and alanine aminotransferase (ALT, 279.1 IU/L) were significantly elevated up to 851.4 IU/L and 800.2 IU/L by the intake of HCHG (Figure 4E,F). Consumption of PCO and ATV significantly lowered HCHG-heightened AST level up to 455.9 IU/L and 673.1 IU/L, and ALT level by 541.5 IU/L and 699.9 IU/L, respectively. Notably, ATV in combination with PCO (i.e., ATV+PCO) displayed better efficacy than ATV alone, as evidenced by ~15% lower AST and ALT levels.




Figure 4. A comparative plasma levels of (A) malondialdehyde (MDA), (B) sulphydryl content, (C) ferric ion reduction ability (FRA), (D) paraoxonase (PON) activity, (E) aspartate aminotransferase (AST), and (F) alanine aminotransferase (ALT) activities of zebrafish after 12 weeks of intake of the specified diets. ND, HC, HG, PCO, and ATV are abbreviations for normal diet, high cholesterol, high galactose, policosanol, and atorvastatin, respectively. The *** highlight statistical significance at $p < 0.001$ vs. HCHG groups. The $^{++}$ and $^{+++}$ depict a statistical significance at $p < 0.01$ and $p < 0.001$ compared to the ATV group. The ^{ss} and ^{sss} depict a statistical significance at $p < 0.01$ and $p < 0.001$ compared to the PCO group. “ns” represent a non-significant difference ($p > 0.05$).

2.5. Functionality Evaluation of Plasma in the Zebrafish Embryo

The functionality of plasma obtained after 12 weeks of consumption of the designated diets was examined by microinjecting it into zebrafish embryos. The survivability of embryos received plasma from the HCHG group showed an adverse effect on survivability, which started to decline at 5 h post injection (83.3%) and finally reached 52.2% at 72 h, which is ~1.5-fold lower than the embryos survivability observed in the ND (control) group (80.2%) at 72 h post injection (Figure 5A). A ~1.4-fold higher embryo survivability (71.3%) was observed in the embryos that received plasma from the PCO-supplemented group compared to the survivability of the HCHG group at 72 h. Interestingly, the embryos that were injected with plasma from the ATV supplement group showed a pattern of poor embryo survivability that parallels to the effect noticed in embryos that received plasma from the HCHG group. In contrast, embryos from the ATV+PCO-supplemented group showed a substantial enhancement in embryo survivability (64%), which was approximately 1.2-fold higher than that noticed in the ATV and HCHG groups at 72 h.

Most of the embryos from the HCHG and ATV groups displayed slight developmental abnormalities along with reduced somite counts (18–22) (Figure 5B,C,F,H). Unlike most embryos in the ND, PCO, and ATV+PCO groups, which showed fewer developmental defects and higher somite counts (27–32).

The dihydroethidium (DHE) and acridine orange (AO) fluorescent staining revealed ~4.5-fold higher ROS generation and apoptosis in the embryos that received the plasma from the HCHG group compared to the ND group (Figure 5D,E,G). Compared to the HCHG group, significantly lower ROS and apoptosis were noticed in the embryos that

injected with the plasma from the PCO, ATV, and ATV+PCO groups. Notably, compared to the ATV group, a substantial 2.1-fold and 1.5-fold reduction in ROS and 2-fold and 1.4-fold reduction in apoptosis were measured in the PCO and ATV+PCO groups, respectively.




Figure 5. Embryos microinjection with plasma obtained from the blood of zebrafish consuming the designated diets for 12 weeks. **(A)** Embryo survivability kinetics during 72 h post-injection. **(B)** Morphology of developing embryos at 24 h and 72 h post-injections. **(C)** Image depicting somite numbers in embryos assessed at 48 h post-treatment. **(D,E)** Dihydroethidium (DHE) and acridine orange (AO), fluorescent staining, respectively. Quantification of **(F)** the mean value of somite numbers, **(G)** DHE and AO fluorescent intensity, respectively. The *** and ### highlight statistical significance at $p < 0.001$ vs. HCHG groups. **(H)** Morphological view of embryos at 144 h post-injection; brown arrow depicts uninflated swimming bladder, black arrow highlights tail fin curvature, blue arrow depicts back bending, red and green arrows highlight yolk sac and pericardial edema. ND, HC, HG, PCO, and ATV are abbreviations for normal diet, high cholesterol, high galactose, policosanol, and atorvastatin, respectively. The signs * and *** highlight statistical significance at $p < 0.05$ and $p < 0.001$, respectively, vs. HCHG groups. The † and †† depict a statistical significance at $p < 0.05$ and $p < 0.01$ compared to the ATV group. The § depicts a statistical significance at $p < 0.05$ compared to the PCO group. “ns” represents a non-significant difference ($p > 0.05$).

At 144 h post-injection, some of the embryos (~20%) in the HCHG and ATV groups appeared with an tail fin curvature (highlighted by black arrow head), back bending (indicated by blue arrow head), yolk sac edema (indicated by green arrow head), pericardial edema (highlighted by red arrow head), uninflated swimming bladder (highlighted by brown arrow), altered stationary posture, and retarded swimming activity (Figure 5H, Supplementary Video S1). Unlike most of the embryos in the ND, PCO, and ATV+PCO groups, which displayed an appropriate stationary position, an inflated swimming bladder, and a rigorous swimming pattern with no severe developmental deformities.

2.6. Histopathological Evaluation of the Liver

The H&E images of the liver suggest the highest neutrophil counts in the HCHG group were significantly 4.5-fold higher than the neutrophil counts in the ND (control) group (Figure 6A,B,F). The consumption of PCO and ATV+PCO showed a 4.7-fold and 3.2-fold reduction in neutrophil counts related to the HCHG group, respectively. A non-significant impact of ATV alone was detected on the reduction in HCHG heightened neutrophil counts.




Figure 6. A comparative hepatic histology of zebrafish after 12-week intake of the specified diets. (A,B) Hematoxylin and eosin (H&E) staining captured at 400× and 1000× magnification, respectively. (C) Immunohistochemical (IHC) imaging to detect the interleukin (IL)-6. (D) Oil red O (ORO) staining. (E) Dihydroethidium (DHE) fluorescent staining. Quantification of (F) neutrophils, (G) IHC-stained area, (H) ORO-stained area, and (I) DHE fluorescent intensity. The semi-quantitative evaluation of neutrophils was assessed under a microscope in a standardized 1.23 mm² area, examining five fields per section across three independent replicates. ND, HC, HG, PCO, and ATV are abbreviations for normal diet, high cholesterol, high galactose, policosanols, and atorvastatin, respectively. The signs *, **, and *** highlight statistical significance at $p < 0.05$, $p < 0.01$, and $p < 0.001$, respectively, vs. HCHG groups. The †† and ††† depict a statistical significance at $p < 0.01$ and $p < 0.001$ compared to the ATV group. The §§ depicts a statistical significance at $p < 0.01$ compared to the PCO group. “ns” represents a non-significant difference ($p > 0.05$).

The IHC staining revealed the highest interleukin (IL)-6-stained area (14.9%) in the HCHG group, which was effectively mitigated to 8.6% and 10.2% by supplementation with PCO and ATV+PCO, respectively (Figure 6C,G). In contrast, supplementation with ATV alone did not significantly prevent HCHG-triggered IL-6 production. The ORO staining revealed an 18.1-fold higher accumulation of fat in the HCHG group compared to the ND group (Figure 6D,H). Supplementation of PCO, ATV, and ATV+PCO substantially inhibited the fat deposition by 4.7-fold ($p < 0.001$), 1.2-fold ($p < 0.05$), and 5.9-fold ($p < 0.001$), respectively, compared to the fat deposited in the HCHG group. Compared to the ATV alone group, the PCO- and ATV+PCO-supplemented groups showed a significantly 3.8- and 4.8-fold reduced fat accumulation, respectively.

A substantial 2.6-fold enhancement in DHE fluorescent intensity related to ROS production was detected in the hepatic section of the HCHG group compared with the ND (control) group (Figure 6E,I). PCO supplementation with HCHG effectively diminished the HCHG-induced increase in DHE fluorescent intensity by 2.4-fold. The ATV alone failed to inhibit ROS production; however, in combination with PCO (i.e., ATV+PCO), a 1.8-fold diminished DHE fluorescent intensity was observed related to the HCHG group.

2.7. Histological Evaluation of Kidney

The H&E staining of the kidney section of HCHG groups revealed a disorganized arrangement of distal and proximal tubular structures with a heavy presence of broad tubular lumen and debris in the lumen (Figure 7A). The PCO intake with HCHG substantially minimizes the HCHG-imparted kidney morphological alteration, though a minor occurrence of dilated tubular lumen was noticed. In contrast, the non-substantial protective effect of ATV was observed against the HCHG-induced disorganized tubular structure and elevated tubular lumen and debris. Whereas ATV in combination with PCO (ATV+PCO) perceived a substantial inhibitory effect on the HCHG-disturbed tubular structure; however, a minor presence of dilated tubular lumen was noticed.

The ORO staining showed the highest fat accumulation in the HCHG group, which was significantly reduced by 2.7- and 2.5-fold with PCO and ATV+PCO supplementation, respectively (Figure 7B,D). Notably, no significant effect of the ATV-only group was noticed toward fat accumulation triggered by HCHG.

The DHE (Figure 7C,E) staining showed a high level of ROS production in the HCHG-supplemented group, which was notably 5.3 times higher than ROS levels in the ND group. A substantial 2-fold and 1.6-fold decrease in DHE fluorescent intensity was observed in the PCO and ATV+PCO-consumed groups, respectively, compared to the HCHG group. Compared with the ATV+PCO group, the PCO group showed a 1.2-fold ($p < 0.05$) reduction in DHE fluorescence. Supplementation of ATV alone failed to affect HCHG-induced ROS generation.

2.8. Brain Histology

As shown in Figure 8A,B, no serious histological changes have appeared in the brain sections across the groups. Nevertheless, related to the ND group, the HCHG-supplemented group showed a higher prevalence of monocular cells with transparent zones and vacuolation in the tectum optic (TeO) and the periventricular gray zone (PGZ) of the brain section. These alterations are notably minimized following the intake of PCO and ATV+PCO.




Figure 7. A comparative effect of 12 weeks' intake of different diets on the kidneys of zebrafish. (A) Hematoxylin and eosin (H&E) staining; PT and DT represent the proximal and distal tubules, while blue and red arrows depict the elevated tubular lumen and cellular debris in the lumen. (B) Oil red O (ORO) staining. (C) Dihydroethidium (DHE) fluorescent staining. Quantification of (D) ORO-stained area, and (E) DHE fluorescent intensity. ND, HC, HG, PCO, and ATV are abbreviations for normal diet, high cholesterol, high galactose, policosanols, and atorvastatin, respectively. The sign *** highlight statistical significance at $p < 0.001$, respectively, vs. HCHG groups. The $^{++}$ and $^{+++}$ depict a statistical significance at $p < 0.01$ and $p < 0.001$ compared to the ATV group. The § depicts a statistical significance at $p < 0.05$ compared to the PCO group. "ns" represents a non-significant difference ($p > 0.05$).

Relative to the ND group, the HCHG group displayed 2.3-, 2.7-, and 2.3-fold higher DHE, AO fluorescent intensities, and senescent-positive cells, respectively, indicating a high level of ROS, apoptosis, and cellular senescence (Figure 8C–J). The brain section of the PCO-supplemented group displayed a 1.8-fold, 2.1-fold, and 2.1-fold reduction in ROS level, apoptosis, and senescent positive cells relative to the HCHG-supplemented group. Likewise, ATV+PCO-supplemented groups showed significantly lower ROS, apoptosis, and senescence than the HCHG group, and the effect is comparable to the effect observed in the PCO-supplemented group. Nonetheless, ATV alone did not affect the reduction in HCHG-triggered ROS, apoptosis, or senescence in the brain.




Figure 8. A comparative effect of 12 weeks of intake of different diets on the brain of zebrafish. (A,B) Hematoxylin and eosin (H&E) staining at 40× and 400× magnification. Fluorescent staining for (C) dihydroethidium (DHE) and (D) acridine orange (AO). (E) Merged images of DHE and AO-stained section. White and yellow arrows highlight the periventricular gray zone (PGZ) and valvular cerebella (Val). (F) Senescent-associated β -galactosidase (SA- β -gal) staining. (G) Images with blue colored senescent positive cells interchanged with red color using the Image J platform (<https://image.net/ij>, assessed on 6 June 2025, version 1.53). The color exchange was performed to improve the visibility of the senescent area at the ImageJ platform at a blue color threshold value of 0–120. (H–J) Quantification of the DHE and AO-fluorescent intensities and senescent stained area, respectively. ND, HC, HG, PCO, and ATV are abbreviations for normal diet, high cholesterol, high galactose, policosanols, and atorvastatin, respectively. The signs *, **, and *** highlight statistical significance at $p < 0.05$, $p < 0.01$, and $p < 0.001$, respectively, vs. HCHG groups. The †† and ††† depict a statistical significance at $p < 0.01$ and $p < 0.001$ compared to the ATV group. “ns” represents a non-significant difference ($p > 0.05$).

2.9. Histological Evaluation of the Eye (Retina)

The H&E staining of the retina showed histological changes around the inner nuclear layer (INL) and outer nuclear layer (ONL) (Figure 9A). In the ND (control) group, a densely packed, broad INL and ONL region appeared, which was substantially reduced after 12 weeks of HCHG intake. When PCO was supplemented with HCHG, a substantial protection of INL and ONL degeneration was noticed compared to the HCHG-supplemented group. In contrast, no visible effect of ATV was observed on the HCHG-induced histological changes; however, ATV in combination with PCO (ATV+PCO) effectively mitigates the HCHG-triggered histological alterations, particularly in the INL and ONL regions of the retina.




Figure 9. A comparative histological analysis of zebrafish eyes (retina) after 12 weeks of intake of the designated diets. (A) Hematoxylin and eosin (H&E) staining; INL and ONL abbreviate for inner nuclear layer and outer nuclear layer, respectively. (B) Dihydroethidium (DHE), (C) acridine orange-fluorescent staining, and (D) merged images of DHE and AO staining. (E) Immunohistochemical (IHC) images for myelin sheath. [Scale bar, 100 μm]. (F–H) Quantitative assessment of fluorescent intensities based on DHE, AO, and myelin, respectively. ND, HC, HG, PCO, and ATV are abbreviations for normal diet, high cholesterol, high galactose, policosanol, and atorvastatin, respectively. The signs ** and *** highlight statistical significance at $p < 0.01$ and $p < 0.001$, respectively, vs. HCHG groups. The [†] and ^{††} depict a statistical significance at $p < 0.05$ and $p < 0.01$ compared to the ATV group. The ^{§§} depict statistical significance at $p < 0.01$ compared to the PCO group. “ns” represent a non-significant difference ($p > 0.05$).

DHE and AO fluorescence revealed pronounced ROS accumulation and apoptosis in the retinal pigmented epithelium (RPE) layer and photoreceptor layer (PRL) of the HCHG group. These levels were markedly elevated, showing 29.6-fold and 22.7-fold increases, respectively, compared with the ND (control) group (Figure 9B–D,E,G). Supplementation with PCO and ATV+PCO substantially attenuated HCHG-induced ROS generation by 12.9-fold and 3.2-fold, respectively, while apoptosis was decreased by 14.1-fold and 3.1-fold. Notably, the PCO consumed group exhibited a ~4.5-fold ($p < 0.01$) reduction in ROS

production and apoptosis relative to the ATV+PCO group. In contrast, intake of ATV alone failed to exert a significant effect on the elevated ROS and apoptosis induced by HCHG.

The myelin-associated fluorescent intensity was maximum in the ND-(control) group that was substantially diminished under the HCHG group, which was effectively prevented by PCO and ATV+PCO supplementation (Figure 9E,H). Compared to the HCHG group, myelin-specific fluorescence increased by 10.4-fold in the PCO group and 8.7-fold in the ATV+PCO-supplemented group. In contrast, ATV alone did not display substantial protection against HCHG-induced demyelination.

2.10. Testis Histology

A 3.6-fold higher interstitial space and 2.1-fold reduced spermatozoa counts were detected in the HCHG-supplemented group compared to the ND (control) group (Figure 10A,B,D,E). PCO supplementation minimizes the HCHG-heightened interstitial space and enhances spermatozoa counts by 2.8-fold and 1.9-fold, respectively. In contrast, no notable effect of ATV on preventing HCHG-induced changes in testicular histology was observed. However, when ATV was used in combination with PCO (i.e., ATV+PCO), a significant 1.5-fold reduction in the interstitial space and a 1.6-fold elevation in spermatozoa numbers compared to HCHG had appeared.




Figure 10. A comparative testis histology of zebrafish after 12 weeks of intake of the designated diets. (A) Hematoxylin and eosin (H&E) staining; ST: spermatocytes, SZ: spermatozoa. (B) interstitial space. (C) Dihydroethidium (DHE) fluorescent staining. Quantification of (D) interstitial space between seminiferous tubules, (E) spermatozoa counts, and (F) DHE fluorescent intensity. ND, HC, HG, PCO, and ATV are abbreviations for normal diet, high cholesterol, high galactose, policosanols, and atorvastatin, respectively. The signs *, **, and *** highlight statistical significance at $p < 0.05$, $p < 0.01$, and $p < 0.001$, respectively, vs. HCHG groups. The †, ††, and ††† indicate statistical significance at $p < 0.05$, $p < 0.01$, and $p < 0.001$, respectively, compared to the ATV group. The § and §§ depict statistical significance at $p < 0.05$ and $p < 0.01$, respectively, compared to the PCO group. “ns” represent a non-significant difference ($p > 0.05$).

The DHE (Figure 10C,F) staining revealed the maximum fluorescence in the HCHG group, which was reduced by PCO and ATV+PCO supplementation to 1.8-fold and 1.4-fold, respectively. Unlike PCO, and ATV+PCO, no substantial effect of ATV alone supplementation was observed on HCHG-elevated DHE fluorescent intensity. In contrast, ATV combined with PCO (ATV+PCO) reduced DHE fluorescence intensity and senescence by 1.5-fold compared with the HCHG group.

2.11. Ovary Histology

The H&E staining of the ovary spotted with a high prevalence of pre-vitellogenic oocytes (88.1%) and reduced early (9.8%) and mature vitellogenic oocytes (2.1%) in the HCHG group, which significantly differed from the ND (control) group (Figure 11A,D,C). Supplementation with PCO and ATV+PCO improved HCHG-triggered oocyte counts; however, the quantitative difference was not statistically significant.




Figure 11. The comparative effect of 12 weeks of intake of the different dietary formulations on the ovary of zebrafish. (A) Hematoxylin and eosin (H&E) staining; P, E, and M depict the pre-, early, and mature vitellogenic oocytes, respectively. (B) Dihydroethidium (DHE) fluorescent staining. Quantification of (C) pre-vitellogenic oocytes, (D) early and mature-vitellogenic oocytes, and (E) DHE fluorescent intensity. ND, HCHG, PCO, and ATV are abbreviations for normal diet, high cholesterol, high galactose, policosanols, and atorvastatin, respectively. The signs *, **, and *** highlight statistical significance at $p < 0.05$, $p < 0.01$, and $p < 0.001$, respectively, vs. HCHG groups. The † and †† depict a statistical significance at $p < 0.05$, $p < 0.01$, and $p < 0.001$ compared to the ATV group. “ns” represents a non-significant difference ($p > 0.05$).

A 5.6-fold higher DHE fluorescent intensity was observed in the HCHG-supplemented group related to the ND group (Figure 11B,E). Supplementation with PCO and ATV+PCO significantly reduced the HCHG-triggered DHE fluorescence by 1.9-fold and 1.5-fold,

respectively. No statistically significant reduction in HCHG-elevated DHE fluorescence was observed with ATV alone.

2.12. Embryo Production Ability of Zebrafish

As shown in Figure 12A, the embryos' production ability between the groups varied substantially from 193.2 ± 16.9 to 360.0 ± 55.7 , with the highest average embryo production (360.0 ± 55.7) in the PCO-supplemented group, which is analogous to the embryo production observed in the ND (353.8 ± 31.2) control group. A severe detrimental effect of HCHG supplementation on embryo production (193.2 ± 16.9) was noticed, which was significantly 1.8-fold inferior to the embryo production noticed in the ND consumed group. The HCHG-induced inhibitory effect on embryo production was countered by the intake of PCO, as reflected by ~1.8-fold higher embryo production in the PCO-supplemented group compared to the HCHG group. An insignificant effect of ATV was observed in preventing HCHG-impaired embryo production. However, ATV in combination with PCO (ATV+PCO) counteracts HCHG, as evidenced by a ~1.5-fold increase in embryo production than to the HCHG group.




Figure 12. The comparative impact of 12-week dietary interventions on (A) zebrafish embryos' production ability, (B) survivability, and (C) hatching of embryos. (D) Pictorial view of the embryos at 144 h post fertilization; brown arrow depicts uninflated swimming bladder, black arrow highlights tail fin curvature, blue arrow depicts back bending, and red and green arrows highlight yolk sac and pericardial edema. ND, HC, HG, PCO, and ATV are abbreviations for normal diet, high cholesterol, high galactose, policosanols, and atorvastatin, respectively. The signs * and ** highlight statistical significance at $p < 0.05$ and $p < 0.01$, respectively, vs. HCHG groups. The [†] and ^{††} depict a statistical significance at $p < 0.05$ and $p < 0.01$ compared to the ATV group. "ns" represents a non-significant difference ($p > 0.05$).

Furthermore, the survivability analysis revealed the least survivability for embryos from the HCHG group, which was 44.5% at 96 h post fertilization (hpf) (Figure 12B). Similarly, the ATV-supplemented group showed poor embryo survival (48.2%) at 96 hpf. Unlike this, embryos from the PCO- and ATV+PCO-supplemented groups showed 80.6% and 68.3% survivability, respectively, at 96 hpf, which was significantly more than the survivability of the HCHG- and ATV-consumed groups (Figure 12B). Consistently, the least embryos hatching (~45%) were noticed in the HCHG group and ATV-supplemented

groups at 96 hpf (Figure 12C). Contrary to this, the embryos from the PCO- and ATV+PCO-supplemented groups displayed a significantly improved embryo hatching of 80.1% and 71.1% at 96 hpf. In addition, ~23% of the survived embryos (at 96 hpf) in the HCHG- and ATV-supplemented group emerged with developmental defect mainly as tail fin curvature (indicated by black arrowhead), back bending (indicated by blue arrowhead), uninflated swimming bladder (indicated by brown arrow), yolk sac edema (highlighted by red arrowhead), and pericardial edema (highlighted by green arrowhead) (Figure 12D). Contrary to this, the majority of embryos in the PCO and ATV+PCO groups appeared without any teratogenic defects; however, minor back bending and tail fin curvature were noticed in some embryos.

3. Discussion

Intake of high cholesterol and high galactose provokes a variety of adverse events, leading to detrimental effects on various organs. Combined supplementation with HCHG served as a robust dietary approach for metabolic disorders that parallel the pathophysiology of human disease [37]. Previously, several studies utilized HC (1–8%) and HG (30%) to induce dyslipidemia, metabolic stress, fatty liver, aging, retinal damage, cataract, and different organ impairment in animal models [38–41]. Following earlier studies, intentional exposure of HC (4%) and HG (30%) was utilized as a dietary supplement to induce a variety of pathological events in the zebrafish, and the efficacy of PCO, ATV, and ATV+PCO was assessed to mitigate the induced pathological changes. In the present study, HCHG consumption for 12 weeks resulted in higher zebrafish mortality, which was notably protected by PCO and ATV+PCO, providing evidence that PCO alone and in combination with ATV impart a preventive effect against HCHG-induced metabolic toxicity.

ATV has gained wide acceptance for the treatment of dyslipidemia owing to its ability to competitively inhibit HMG-CoA reductase, a major rate-limiting enzyme in cholesterol biosynthesis [3]. Contrary to its natural substrate (HMG-CoA), ATV showed a roughly 1000-fold higher affinity for HMG-CoA reductase, thereby exerting a substantial impact on cholesterol biosynthesis inhibition [42]. Also, PCO has been recognized to modulate the HMG-CoA reductase and lower cholesterol biosynthesis [20]. Besides PCO's substantial role in cholesterol efflux capacity [21] and cholesterol catabolism in the liver, which leads to bile acid production and subsequent fecal excretion [43,44], plays an essential role in reducing cholesterol levels. Consistent with the literature, herein, supplementation of ATV and PCO proved effective in reducing HCHG-elevated dyslipidemia. However, in combination (ATV+PCO), TC, TG, and LDL-C levels are significantly lower compared with the individual effects of ATV or PCO alone. Notably, unlike the ATV, only PCO augments HDL-C levels; however, ATV in combination with PCO (i.e., ATV+PCO) substantially augments HDL-C and HDL-C/TC levels. A notable effect of PCO inhibiting CETP has been recognized to improve the HDL-C levels [45]. In addition, PCO positively affects the expression of Apolipoprotein A-I (apoA-I) [21], a major HDL protein that enhances HDL-C levels. The combined results of the blood lipoprotein profile confirmed that ATV+PCO effectively mitigates HCHG-induced dyslipidemia, which was substantially better than the individual effects of PCO and ATV.

The negative effects of galactose, a high-fat diet, and oxidative stress have been acknowledged for insulin sensitization and secretion, consequently causing hyperglycemia [46,47]. Accumulating evidence links statins, including ATV, to the onset of type II diabetes [12–14]. Mechanistic studies in diabetic rats demonstrated that ATV impairs insulin sensitization, suggesting a direct adverse effect on glycemic regulation [48]. In contrast, reports established an affirmative impact of PCO on insulin secretion and sensitization, mediated by the AMPK/PI3K/AKT signaling pathway [25]. Herein, in accordance

with the literature, we have observed a positive effect of PCO but no supportive effect of ATV in mitigating the elevated blood glucose level associated with HCHG. Interestingly, ATV in combination with PCO (ATV+PCO) effectively balanced the HCHG elevated blood glucose levels.

A consistent high exposure of cholesterol and galactose have been linked to oxidative stress, as evident by elevated MDA levels and reduced sulfhydryl content, which are critical indicators of oxidative stress associated with various diseases [49–51]. Similarly, reduced antioxidant variables concerning FRA and PON activities were observed in the HCHG groups, reflecting the high oxidative environment. The effect of PCO has been recognized to inhibit MDA production [52] and to elevate sulfhydryl content, FRA, and PON activities [41], reflecting PCO's substantial effect in mitigating oxidative stress and strengthening antioxidant defense. Galactose is known to induce galactosemia and the subsequent production of advanced glycation end products (AGEs), which cause several detrimental effects, including oxidative stress [53]. Fortunately, PCO harbors antiglycation properties that inhibit AGE production [26], and thus play an additional role in diminishing HCHG-elevated ROS levels. Some studies suggest a proactive role for statins in oxidative stress, as measured by increased blood and tissue MDA and reduced glutathione content; nevertheless, we did not observe any augmentation of HCHG-induced oxidative stress in response to ATV. Of note, the present study provides clear evidence that ATV alone is nonresponsive; however, in combination with PCO (ATV+PCO), it effectively mitigates HCHG-induced oxidative stress and improves antioxidant variables.

Moreover, plasma from the PCO groups showed improved zebrafish embryo viability, likely due to lower levels of oxidative species and higher antioxidant levels, which reduced ROS generation, developmental defects, and apoptotic cell death. In contrast, embryos from the ATV group showed elevated ROS levels and reduced survival, correlating with a high oxidative load and decreased plasma antioxidant levels. Notably, the plasma from the ATV+PCO group shows a low oxidative status and high antioxidant levels, leading to reduced ROS production, fewer teratogenic effects, and higher embryo survival. However, to establish this relationship, a more detailed mechanistic study is needed to confirm the notion.

High cholesterol is known to cause fatty liver [54], whereas high galactose intake leads to oxidative stress and the generation of inflammatory cytokines such as IL-6, IL-10, and TNF- α [55]. Herein, the HCHG caused hepatotoxicity, countered by the consumption of PCO. The outcomes are consistent with the reports describing a definite effect of PCO on fatty liver, inflammation, and oxidative stress provoked by external factors. The accumulating reports depict ATV hepatotoxicity accompanied by oxidative stress [56]. However, in the present study, ATV showed nonresponsive to HCHG, elevated hepatic IL-6 production, and induction of oxidative stress. In contrast, when ATV was supplemented with PCO, it effectively minimized HCHG-induced IL-6 production, ROS generation, and fatty liver, suggesting that ATV in combination with PCO provides substantial hepatoprotection against HCHG-triggered events. Consistent with the histological outcomes, the HCHG elevated plasma hepatic function biomarkers (AST and ALT) remained unchanged in response to ATV alone but were significantly alleviated by the combination of ATV+PCO.

High galactose has been recognized to damage the kidney [57] through the induction of oxidative stress and formation and accumulation of AGEs [58]. Herein, PCO displayed a substantial effect in preventing HCHG-induced damage, minimizing the HCHG-induced elevation in ROS generation, and exerting an antiglycation effect, which underlies its kidney-protective effect. The notion is consistent with studies documenting the profound negative impact of oxidative stress and AGEs on kidney health [58]. Although previous studies have linked ATV to kidney toxicity [6]; we observed no significant additional

histopathological damage from ATV that exacerbated HCHG-induced injury. Moreover, the combination of ATV with PCO (ATV+PCO) substantially protected the kidney from HCHG-induced oxidative stress. The histological outcomes are in line with the findings of plasma sulfhydryl content, where diminished sulfhydryl levels appeared in the HCHG and ATV-supplemented groups, reflecting poor kidney health. Notably, low sulfhydryl content has been recognized as a marker linked with a variety of kidney diseases [59].

Galactose negatively affects brain health and provokes brain aging, mediated by its effects on cellular antioxidants and the induction of ROS [60,61]. In addition, studies deciphered that galactose accumulation in the brain initiates AGE formation, leading to brain damage and cognitive impairment [62]. The positive effect of PCO on ROS inhibition leads to events that protect the brain from HCHG-induced apoptosis and senescence, as these events are directly correlated with ROS-induced oxidative stress [63,64]. ATV failed to establish any protective effect; however, in combination with PCO (i.e., ATV+PCO), a notable impact on mitigating HCHG-triggered ROS generation and, consequently, inhibiting apoptosis and senescence was observed. In addition to a direct impact on brain ROS, better kidney and liver health in the PCO and ATV+PCO groups positively impacted brain health impaired by HCHG consumption. It has been documented that excessive hepatic lipid accumulation provokes events that alter blood–brain barrier permeability and facilitate the passage of immune cells and toxic materials into the brain, leading to brain impairment, underscoring the liver–brain axis [65]. Likewise, poor kidney health and oxidative stress provoke brain damage and neuropsychiatric impairments, highlighting the kidney–brain axis [66].

High cholesterol and high galactose intake facilitate events that eventually lead to eye problems such as cataracts and retinal damage [67,68]. Also, herein, a substantial histological change in the retinal tissue, with a high prevalence of ROS, apoptosis, and senescence, was observed in response to HCHG. The PCO and ATV+PCO showed varying degrees of protective effects against HCHG-induced eye damage, whereas ATV alone had no protective effect. The cellular antioxidant activity of PCO and ATV+PCO is likely the key contributor to the eye protection caused by the HCHG. The perspective aligns with earlier reports documenting the antioxidant's important role in protecting eye damage [68]. In addition, reduced apoptosis and increased myelination in the PCO and ATV+PCO groups can be justified by the lowest levels of ROS in these groups, as ROS-induced oxidative stress has been recognized as a key driver of apoptosis [64] and demyelination [69].

High cholesterol and high galactose have been known to cause reproductive organ damage [70], and we also observed elevated ROS levels and histological changes in the testes and ovaries. Consumption of PCO alone or in combination with ATV effectively protected the ovary and testis from HCHG-induced events. However, no effect of ATV alone was observed in preventing HCHG destructive events. Notably, in the testis, PCO alone and in combination with ATV reversed the compromised spermatozoa counts and elevated ROS levels, whereas ATV alone failed to alter these changes. Accumulating literature suggests statins, including ATV, have adverse effects on testis and reproductive health [11]. However, in the present 12-week consumption study, ATV did not aggravate the HCHG-induced testicular damage. As antioxidants have been shown to affect oxidative stress and protect the ovary [71] and testis [72], we speculate that PCO and ATV+PCO have substantial protective effect on the ovary and testis, associated with their impact on oxidative stress, as evidenced by the lowest ROS production in these groups.

Limitation of the study: the study outcomes (biochemical and histological) are derived exclusively from surviving zebrafish, which may reflect the resistant population. Consequently, some degree of bias in the reported effects cannot be completely excluded. Also, the effects of ATV and ATV+PCO on a normal diet need to be explored to assess their

responses under normolipidemic conditions. Although zebrafish share many similarities with humans, important species-specific differences must be considered while comparing results with the human context. For instance, apolipoproteins constitute 10% of plasma lipoproteins in humans, whereas it accounts for nearly 36% in zebrafish [73]. In addition, zebrafish LDL contains higher triglycerides and lower cholesterol ester content than human LDL [73]. Furthermore, zebrafish are cold-blooded (ectothermic) [36], unlike humans, who are warm-blooded (endothermic), leading to substantial differences in metabolic rate regulation in response to environmental factors [74]; hence, the results obtained need to be tested on some warm-blooded animals. Due to these substantial variations, results obtained from zebrafish must be interpreted rationally when compared with the human response.

4. Materials and Methods

4.1. Materials

Policosanol (batch#310030324), containing a mixture of eight-chain long aliphatic alcohols (LCAA), was provided by Raydel Pty Ltd (Thornleigh, NSW, Australia). A detailed specification and certificate of analysis is enclosed as Supplementary Figure S1. Atorvastatin (PHR1422-1G) was procured from Sigma-Aldrich (St. Louis, MO, USA). The antibodies against IL-6 (ab9324) were obtained from Abcam, Cambridge, UK, while the polyclonal antibodies against myelin (0.7 mg/nL) were raised in rabbits and kindly provided by Prof. Cheol-Hee Kim (Developmental Genetics Laboratory, Chungnam National University, Daejeon, Republic of Korea). The goat anti-rabbit fluorescently tagged antibodies (Alexa FluorTM⁴⁰⁵, A-31556) were obtained from Thermo Fisher Scientific (Waltham, MA, USA). All the other chemicals and reagents else stated are of analytical grade and used as supplied. A detailed chemical and reagents list is provided in Supplementary Materials Section S1.

4.2. Zebrafish Maintenance

Twelve-week-old zebrafish were housed in tanks supplied with continuously flowing water. The water temperature was maintained at 28 °C, and the zebrafish culture room was maintained on a 14 h light:10 h dark photoperiod. All husbandry and experimental procedures complied with the Animal Care Committee as adopted by Raydel Research Institute (approval code: RRI-24-001, approved on 2 September 2024). The zebrafish were provided with a normal tetrabit (ND, Tetrabit D49304, Melle, Germany). Prior to the initiation of the experiment, the zebrafish were allowed to acclimate to these conditions for 1 week.

4.3. Preparation of Different Diets and Feeding of Zebrafish

ND was used as the basic food to formulate different diets. ND was mixed with 4% (*w/w*) cholesterol and 30% (*w/w*) galactose to form the high-cholesterol (HC) and high-galactose (HG) diet and was abbreviated as HCHG. The HCHG diets were mixed with either 0.1% (*w/w*) atorvastatin (ATV) or 0.1% (*w/w*) policosanol (PCO) and were abbreviated as HCHG+ATV and HCHG+PCO, respectively. Similarly, HCHG diets were mixed with 0.1% each of ATV and PCO, and the resulting diet was abbreviated as HCHG+ATV+PCO.

Initially, 140 zebrafish were randomly distributed across two tanks using spatial techniques. Tank I contains 28 zebrafish, whereas tank II contains 112 zebrafish, which were fed with ND and HCHG diet, respectively, for 4 weeks (pre-feeding) (Figure 13). Post 4 weeks of feeding tank I, zebrafish (*n* = 28) were continuously maintained on the ND diet and designated as the ND (control) group. The tank II zebrafish (*n* = 112) were randomly divided further into four groups, each containing equal numbers (*n* = 28/group), and fed designated diets. The zebrafish fed with the HCHG diet were named the HCHG-supplemented group.

While zebrafish fed with HCHG+PCO, HCHG+ATV, and HCHG+ATV+PCO were named as HCHG+PCO, HCHG+ATV, and HCHG+ATV+PCO supplemented groups, respectively. Notably, zebrafish of each group ($n = 28$) were distributed into four tanks [$n = 28$ (7×4 tanks)] (Figure 13). The zebrafish were given their respective diets twice daily (9 am and 6 pm). The specified diet, totaling 70 mg, was provided to each tank (at the given time), i.e., 10 mg of diet/fish; therefore, each tank received a total of 140 mg of diet/day. The diet for the specified group was isocaloric; however, caloric values of diets varied substantially between the groups.




Figure 13. Lay out of the feeding study plan and the division of various groups. HC, HG, ATV, and PCO are abbreviated for high cholesterol, high galactose, atorvastatin, and policosanol, respectively.

At the beginning, the food consumption efficacy was assessed to determine zebrafish liking and dislike of the different formulated diets using the earlier described method [41] employing the formula: $[\text{Total food supply (mg)} - \text{remaining food (mg)}] / \text{total food supply (mg)} \times 100$. The remaining food was quantified after 30 min of the food supply. A detailed methodology is provided as the Supplementary Method Section S2.

4.4. Collection of Blood and Organs

After 12 weeks on their assigned diets, zebrafish from all experimental groups were fasted overnight and scarified using hypothermic shock [41]. Blood was obtained from twelve zebrafish per group, yielding ~2 to 5 μL /zebrafish. Samples within each group were combined into a single tube and immediately diluted with phosphate-buffered saline (PBS)-1 mM ethylenediamine-tetraacetic acid (EDTA) at 2:3 (v/v) ratio. The diluted blood samples were centrifuged to separate plasma, which was stored at 4 $^{\circ}\text{C}$ until further analysis. To minimize variability related to feeding and circadian rhythms, blood collection was constantly performed between 9.00 am and 10.30 am for all groups.

For organ collection (liver, kidney, brain, testis, ovaries, and eyes), zebrafish were dissected under a stereomicroscope (Motic SMZ 168; Hong Kong, China), and organs were separately preserved in 10% formalin solution for histological examination.

Notably, the fishes (across the groups) that died before completing 12 weeks of the dietary course were excluded for sample collection (blood and organs). Sample collection was performed only for those who survived the full course.

4.5. Blood Biochemical Evaluation

The blood glucose level was measured with an automated glucose meter (AccuCheck, Roche Basel, Switzerland). The blood plasma lipoprotein profile, including quantification of total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C),

and hepatic function biomarkers aspartate aminotransferase (AST) and alanine aminotransferase (ALT), was determined using commercial kits according to the manufacturers' instructions. A detailed procedure for the detection of blood lipid profile and hepatic function biomarkers is provided as Supplementary Method Section S3.

The blood MDA level was determined by TBARS assay [75]. Whereas plasma sulfhydryl content, ferric ion reduction ability (FRA), and paraoxonase (PON) activity were determined by the earlier described method [75]. A detailed procedure for the plasma estimation of MDA, sulfhydryl content, FRA, and PON activities is provided as Supplementary Method Section S4.

For each biochemical assay, four replicates per group ($n = 4$) were analyzed, and results are reported as mean $\pm$ SEM. Importantly, for the biochemical analysis, samples from different groups were coded with non-revealing numerical codes prior to being assigned for the analysis.

4.6. Microinjection of Plasma into Zebrafish Embryos

Embryos were produced by separating male and female zebrafish using a physical divider inside the breeding tank. After 16 h of separation, the divider was removed and the zebrafish were allowed to mate (~30 min). The produced embryos were collected, washed with water, and preserved in 0.01% (w/v) sea salt solution (containing 1 $\mu\text{g/mL}$ methylene blue). Post 1.5 h fertilization, embryos were divided into five distinct groups ($n = 150/\text{group}$). Each embryo in the ND (control) group received the 10 nL microinjection of plasma obtained from the adult zebrafish fed with the ND diet. While the embryos in the HCHG, HCHG+PCO, HCHG+ATV, and HCHG+ATV+PCO groups, were microinjected with 10 nL of plasma obtained from zebrafish fed HCHG, HCHG+PCO, HCHG+ATV, or HCHG+ATV+PCO diets, respectively. Embryos across the groups were examined under a stereomicroscope (Motic SMZ 168; Hong Kong, China) until 72 h post-treatment to assess embryo death, somite counts, and other developmental defects, following the guidelines of OECD 2019 [76]. At 144 h post-treatment, swimming activity of the developing embryos was recorded.

4.7. Dihydroethidium Ethidium (DHE) and Acridine Orange (AO) Staining of Embryos

Embryos ($n = 10$) were treated with DHE (30 μM) and AO (5 $\mu\text{g/mL}$) solutions according to the previously described method [77]. After 30 min of staining at room temperature (RT), embryos were washed with PBS and examined under a fluorescent microscope. The fluorescent examinations were performed at excitation and emission wavelengths of 585 nm and 615 nm for DHE and 505 nm and 535 nm for AO, respectively. The semi-quantification of the fluorescent intensities of DHE and AO was determined using ImageJ (<https://imagej.net/ij>, version 1.53, assessed on 6 June 2025).

4.8. Hematoxylin and Eosin, and Oil Red O Staining

Different tissues (liver, kidney, heart, testis, ovary, and eyes) were blocked in the FSC22 frozen solution (Leica, Nussloch, Germany) and processed for tissue sectioning (7 μm thick) using a cryo-microtome (CM-1510S Leica, Nussloch, Germany).

Hematoxylin and eosin (H&E) staining was performed as described previously [78] to assess histological changes in different organs. Oil red O (ORO) staining was performed on liver and kidney sections to determine fat accumulation using the methodology described elsewhere [77]. In brief, the tissue section (7 μm thick) was treated for 5 min with 0.1% ORO solution (at 60 $^{\circ}\text{C}$) and subsequently washed with isopropanol (60%) and examined microscopically. Importantly, for the histological analysis, samples (tissue) from different groups were coded with non-revealing numerical codes prior to assignment to the analysis.

4.9. Cellular Senescence and Fluorescent Staining

Cellular senescence in the brain sample was evaluated using senescence-associated β -galactosidase (SA β -gal) staining [41]. The tissue section was incubated with a 0.1% solution of 3-indolyl- β -D-galactopyranoside for 16 h at RT, rinsed with PBS, and analyzed under a microscope for the presence of blue-colored senescent cells.

Levels of reactive oxygen species (ROS) and apoptotic cells were assessed using DHE and AO fluorescent staining, respectively, according to the methodology outlined in Section 4.7.

4.10. Immunohistochemical (IHC) Staining

Interleukin (IL)-6 production in the liver and myelin in the eyes (retina) was examined by the IHC staining. Liver section (7 μ m thick) was incubated with IL-6-specific primary immunoglobulins (1:200 dilution, Abcam ab9324, Cambridge, UK) overnight at 4 °C. Following incubation, the section was rinsed and processed using EnVision HRP polymer kit (Dako, Glostrup, Denmark) which includes HRP-tagged anti-IL-6 immunoglobulin and a chromogenic substrate. Stained sections were subsequently observed under a light microscope.

For retinal analysis, eye section were treated with myelin-specific immunoglobulins (1:200 dilution; rabbit derived, kindly provided by Prof. Cheol-Hee Kim, Developmental Genetics Laboratory, Chungnam National University, Daejeon, Republic of Korea) and incubated overnight at 4 °C. After washing, the section was incubated with Alexa FluorTM405-conjugated secondary immunoglobins (1:400 dilution). Fluorescent signals were visualized using a fluorescent microscope with excitation at 401 nm and emission at 422 nm.

4.11. Ability of Embryo Production, Embryo Survivability, and Hatching Rate

Embryo production across the groups was conducted after 12 weeks of intake of different diets, following the method described in Section 4.6. In brief, six female and three male zebrafish from each group were transferred into three different breeding tanks (each tank containing two female and one male zebrafish) and allowed to mate. The embryos produced across the groups were counted to quantify embryo production ability. The embryos from each group ($n = 100$) were placed in 0.01% sea salt solution and observed under a microscope at 24, 48, 72, and 96 h post fertilization (hpf) to examine survival, hatching, and teratogenic effects.

4.12. Statistical Evaluation

Statistical differences ($p < 0.05$) among multiple groups were evaluated using one-way analysis of variance (ANOVA) followed by Tukey's post hoc analysis, performed with SPSS software (version 29, Chicago, IL, USA). Prior to ANOVA, data normality was assessed using the Kolmogorov–Smirnov test. Pairwise statistical differences between groups ($p < 0.05$) were analyzed using a two-tailed t -test.

5. Conclusions

A 12-week consumption study revealed comparable counter effects of ATV and PCO on dyslipidemia in hyperlipidemic-hyperglycemic zebrafish. Nevertheless, compared with individual supplementation (ATV or PCO), combined supplementation (ATV+PCO) showed notably higher efficacy in restoring the plasma lipid profile. The finding uncovers ATV non-responsiveness to HCHG-induced organ health; however, in combination with PCO (ATV+PCO), it substantially improved antioxidant parameters, inhibition of ROS generation, and protection of varied organs and reproductive health. The study concludes

that combinational therapy using ATV+PCO can mitigate metabolic stress and associated organ damage caused by the chronic exposure of high cholesterol and high galactose. Despite the promising findings, future studies in mammalian (warm-blooded) animals will be helpful to better correlate these results in the context of humans.

Supplementary Materials: The following supporting information can be downloaded at <https://www.mdpi.com/article/10.3390/ph19020237/s1>. Figure S1: Certificate of analysis and composition of policosanol (POL). Section S1: List of chemical and reagents. Section S2: A methodology to determine food consumption efficacy. Sections S3 and S4: A detailed methodology for the quantification of plasma lipid profile, hepatic function biomarkers, malondialdehyde (MDA), sulfhydryl content, ferric ion reduction ability (FRA), and paraoxonase (PON) activity, respectively. Videos S1 and S2: Representative images of embryos swimming at 144 h post injection.

Author Contributions: Conceptualization, K.-H.C.; methodology, A.B., J.-E.K., S.H.L., Y.L., C.J., S.H.B., and K.D.; data curation, writing—original draft preparation, K.-H.C.; writing—review and editing, K.-H.C., supervision, K.-H.C. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: The animal study protocol was approved by Committee of Animal Care and Use of Raydel Research Institute (approval code RRI-24-001, approval date 2 September 2024).

Informed Consent Statement: Not applicable.

Data Availability Statement: The original contributions presented in this study are included in the article/Supplementary Materials. Further inquiries can be directed to the corresponding author.

Conflicts of Interest: All authors are employed by the Raydel HDL Research Institute. The authors declare that the research was conducted in the absence of any commercial and financial relationship that could be constructed as a potential conflict of interest.

References

1. Ballena-Caicedo, J.; Zuzunaga-Montoya, F.E.; Loayza-Castro, J.A.; Vásquez-Romero, L.E.M.; Tapia-Limonchi, R.; De Carrillo, C.I.G.; Vera-Ponce, V.J. Global prevalence of dyslipidemias in the general adult population: A systematic review and meta-analysis. *J. Health Popul. Nutr.* **2025**, *44*, 308. [\[CrossRef\]](#) [\[PubMed\]](#)
2. Dubińska-Magiera, M.; Migocka-Patrzałek, M.; Lewandowski, D.; Daczewska, M.; Jagla, K. Zebrafish as a model for the study of lipid-lowering drug-induced myopathies. *Int. J. Mol. Sci.* **2021**, *22*, 5654. [\[CrossRef\]](#) [\[PubMed\]](#)
3. Adhyaru, B.B.; Jacobson, T.A. Safety and efficacy of statin therapy. *Nat. Rev. Cardiol.* **2018**, *15*, 757–769. [\[CrossRef\]](#) [\[PubMed\]](#)
4. Li, D.; Chen, J.; Zhou, F.; Zhang, W.; Chen, H. Aldo-keto reductase-7A2 protects against atorvastatin-induced hepatotoxicity via Nrf2 activation. *Chem.-Biol. Interact.* **2024**, *393*, 110956. [\[CrossRef\]](#)
5. Eser Faki, H.; Tras, B.; Uney, K. Alpha lipoic acid and vitamin E improve atorvastatin-induced mitochondrial dysfunctions in rats. *Mitochondrion* **2020**, *52*, 83–88. [\[CrossRef\]](#)
6. Pal, S.; Sarkar, A.; Pal, P.B.; Sil, P.C. Protective effect of arjunolic acid against atorvastatin induced hepatic and renal pathophysiology via MAPK, mitochondria and ER dependent pathways. *Biochimie* **2015**, *112*, 20–34. [\[CrossRef\]](#)
7. Bouitbir, J.; Charles, A.-L.; Rasseneur, L.; Dufour, S.; Piquard, F.; Geny, B.; Zoll, J. Atorvastatin treatment reduces exercise capacities in rats: Involvement of mitochondrial impairments and oxidative stress. *J. Appl. Physiol.* **2011**, *111*, 1477–1483. [\[CrossRef\]](#)
8. Mpumbya, R.J.; Ifie, J.E.; Atoki, A.V.; Kembabazi, S.M.; Mbina, S.A.; Kwizera, E.; Akankwasa, G.; Ablinda, M.G.; Bwambele, F.; Robert, S.; et al. Phenolic-rich fraction of *Solanum betaceum* mitigates atorvastatin-induced myotoxicity through antioxidant mechanisms in female wistar rats. *Toxicol. Rep.* **2025**, *14*, 102049. [\[CrossRef\]](#)
9. Kearney, S.; Carr, A.S.; McConville, J.; McCarron, M.O. Rhabdomyolysis after co-prescription of statin and fusidic acid. *BMJ* **2012**, *345*, e6562. [\[CrossRef\]](#)
10. Radcliffe, K.A.; Campbell, W.W. Statin myopathy. *Curr. Neurol. Neurosci. Rep.* **2008**, *8*, 66–72. [\[CrossRef\]](#)
11. Ghosh, S.; Biswas, M. Co-administration of atorvastatin with piperine induces reproductive toxicity in male Wistar rats through oxidative stress induction and downregulation of StAR, CYP11a1, 3 β HSD and 17 β HSD genes. *Reprod. Toxicol.* **2025**, *135*, 108919. [\[CrossRef\]](#) [\[PubMed\]](#)

12. Rajpathak, S.N.; Kumbhani, D.J.; Crandall, J.; Barzilai, N.; Alderman, M.; Ridker, P.M. Statin therapy and risk of developing type 2 diabetes: A meta-analysis. *Diabetes Care* **2009**, *32*, 1924–1929. [[CrossRef](#)] [[PubMed](#)]
13. Ridker, P.M.; Pradhan, A.; MacFadyen, J.G.; Libby, P.; Glynn, R.J. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: An analysis from the JUPITER trial. *Lancet* **2012**, *380*, 565–571. [[CrossRef](#)] [[PubMed](#)]
14. Preiss, D.; Seshasai, S.R.; Welsh, P.; Murphy, S.A.; Ho, J.E.; Waters, D.D.; DeMicco, D.A.; Barter, P.; Cannon, C.P.; Sabatine, M.S.; et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: A meta-analysis. *JAMA* **2011**, *305*, 2556–2564. [[CrossRef](#)]
15. Paolisso, G.; Barbagallo, M.; Petrella, G.; Ragno, E.; Barbieri, M.; Giordano, M.; Varricchio, M. Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients. *Atherosclerosis* **2000**, *150*, 121–127. [[CrossRef](#)]
16. Huptas, S.; Geiss, H.C.; Otto, C.; Parhofer, K.G. Effect of atorvastatin (10 mg/day) on glucose metabolism in patients with the metabolic syndrome. *Am. J. Cardiol.* **2006**, *98*, 66–99. [[CrossRef](#)]
17. Nakamura, T.; Kodama, Y.; Takano, H.; Umetani, K.; Fujioka, D.; Saito, Y.; Kawabata, K.-i.; Obata, J.-E.; Kitta, Y.; Kobayashi, T. Increase in circulating levels of adiponectin after treatment with statin and fibrate in patients with coronary artery disease and hyperlipidemia. *Atherosclerosis* **2007**, *193*, 449–451. [[CrossRef](#)]
18. Cicero, A.F.G.; Colletti, A.; Bajraktari, G.; Descamps, O.; Djuric, D.M.; Ezhov, M.; Fras, Z.; Katsiki, N.; Langlois, M.; Latkovskis, G.; et al. Lipid lowering nutraceuticals in clinical practice: Position paper from an International Lipid Expert Panel. *Arch. Med. Sci.* **2017**, *13*, 965–1005. [[CrossRef](#)]
19. Chen, Z.Y.; Jiao, R.; Ma, K.Y. Cholesterol-lowering nutraceuticals and functional foods. *J. Agric. Food Chem.* **2008**, *56*, 8761–8773. [[CrossRef](#)]
20. Olatunji, L.K.; Jimoh, A.O.; Tukur, U.M.; Imam, M.U. A review of the effects of policosanols on metabolic syndrome. *Clin. Complement. Med. Pharmacol.* **2022**, *2*, 100058. [[CrossRef](#)]
21. Uehara, Y.; Komatsu, T.; Sasaki, K.; Abe, S.; Nakashima, S.; Yamamoto, T.; Kim, J.-E.; Cho, K.-H. Cuban policosanols improves high-density lipoprotein cholesterol efflux capacity in healthy Japanese subjects. *Front. Nutr.* **2024**, *10*, 1297008. [[CrossRef](#)]
22. Cho, K.-H.; Nam, H.-S.; Kim, N.-Y.; Lee, M.-S.; Kang, D.-J. Combination therapy of Cuban policanol (Raydel®, 20 mg) and intensive exercise for 12 weeks resulted in improvements in obesity, hypertension, and dyslipidemia without a decrease in serum coenzyme Q₁₀: Enhancement of lipoproteins quality and antioxidant functionality in obese participants. *Pharmaceuticals* **2024**, *17*, 132. [[CrossRef](#)] [[PubMed](#)]
23. Park, H.-J.; Yadav, D.; Jeong, D.-J.; Kim, S.-J.; Bae, M.-A.; Kim, J.-R.; Cho, K.-H. Short-term consumption of Cuban policosanols lowers aortic and peripheral blood pressure and ameliorates serum lipid parameters in healthy Korean participants: Randomized, double-blinded, and placebo-controlled study. *Int. J. Environ. Res. Public Health* **2019**, *16*, 809. [[CrossRef](#)] [[PubMed](#)]
24. Askarpour, M.; Ghaedi, E.; Roshanravan, N.; Hadi, A.; Mohammadi, H.; Symonds, M.E.; Miraghajani, M. Policosanols supplementation significantly improves blood pressure among adults: A systematic review and meta-analysis of randomized controlled trials. *Complement. Ther. Med.* **2019**, *45*, 89–97. [[CrossRef](#)] [[PubMed](#)]
25. Amini, M.R.; Kazeminejad, S.; Jalalzadeh, M.; Majd, S.S.; Kavyani, Z.; Askari, G.; Hekmatdoost, A. The effects of policosanols supplementation on blood glucose: A systematic review and dose-response meta-analysis of randomized controlled trials. *Diabetes Res. Clin. Pract.* **2024**, *212*, 111709. [[CrossRef](#)]
26. Cho, K.-H.; Kim, S.-J.; Yadav, D.; Kim, J.-Y.; Kim, J.-R. Consumption of Cuban policosanols improves blood pressure and lipid profile via enhancement of HDL functionality in healthy women subjects: Randomized, double-blinded, and placebo-controlled study. *Oxidative Med. Cell Longev.* **2018**, *2018*, 4809525. [[CrossRef](#)]
27. Thorne Research. Policosanols Monograph. *Altern. Med. Rev.* **2004**, *9*, 312–317.
28. Cubeddu, L.X.; Cubeddu, R.J.; Heimowitz, T.; Restrepo, B.; Lamas, G.A.; Weinberg, G.B. Comparative lipid-lowering effects of policosanols and atorvastatin: A randomized, parallel, double-blind, placebo-controlled trial. *Am. Heart J.* **2006**, *152*, 982.e1–982.e5. [[CrossRef](#)]
29. Castaño, G.; Fernández, L.; Mas, R.; Illnait, J.; Mesa, M.; Fernandez, J. Comparison of the effects of policosanols and atorvastatin on lipid profile and platelet aggregation in patients with dyslipidaemia and type 2 diabetes mellitus. *Clin. Drug Investig.* **2003**, *23*, 639–650. [[CrossRef](#)]
30. Castano, G.; Mas, R.; Fernandez, L.; Illnait, J.; Mesa, M.; Alvarez, E.; Lezcay, M. Comparison of the efficacy and tolerability of policosanols with atorvastatin in elderly patients with type II hypercholesterolaemia. *Drugs Aging* **2003**, *20*, 153–163. [[CrossRef](#)]
31. Morales, E.E.; Wingert, R.A. Zebrafish as a model of kidney disease. *Results Probl. Cell Differ.* **2017**, *60*, 55–75.
32. Shimizu, N.; Shiraishi, H.; Hanada, T. Zebrafish as a useful model system for human liver disease. *Cells* **2023**, *12*, 2246. [[CrossRef](#)]
33. Zha, W.; Hu, W.; Ge, C.; Chen, J.; Cao, Z. Zebrafish as a model system for studying reproductive diseases. *Front. Cell Dev. Biol.* **2024**, *12*, 1481634. [[CrossRef](#)] [[PubMed](#)]
34. Seth, A.; Stemple, D.L.; Barroso, I. The emerging use of zebrafish to model metabolic disease. *Dis. Models Mech.* **2013**, *6*, 1080–1088. [[CrossRef](#)] [[PubMed](#)]

35. Fang, L.; Liu, C.; Miller, Y.I. Zebrafish models of dyslipidemia: Relevance to atherosclerosis and angiogenesis. *Transl. Res.* **2014**, *163*, 99–108. [\[CrossRef\]](#) [\[PubMed\]](#)
36. Ka, J.; Jin, S.-W. Zebrafish as an emerging model for dyslipidemia and associated diseases. *J. Lipid Atheroscler.* **2021**, *10*, 42–56. [\[CrossRef\]](#)
37. Bala, S.; Ganz, M.; Babuta, M.; Zhuang, Y.; Csak, T.; Calenda, C.D.; Szabo, G. Steatosis, inflammasome upregulation, and fibrosis are attenuated in miR-155 deficient mice in a high fat-cholesterol-sugar diet-induced model of NASH. *Lab. Investig.* **2021**, *101*, 1540–1549. [\[CrossRef\]](#)
38. Han, J.; Zhang, R.; Zhang, X.; Dong, J.; Chen, M.; Pan, Y.; Liao, Z.; Zhong, M.; He, J.; Wang, F.; et al. Zebrafish model for screening antiatherosclerosis drugs. *Oxidative Med. Cell. Longev.* **2021**, *2021*, 9995401. [\[CrossRef\]](#)
39. Jin, Y.; Kozan, D.; Young, E.D.; Hensley, M.; Shen, M.-C.; Wen, J.; Moll, T.; Anderson, J.L.; Kozan, H.; Rawls, J.F.; et al. A high-cholesterol zebrafish diet promotes hypercholesterolemia and fasting-associated liver steatosis. *J. Lipid Res.* **2024**, *65*, 100637. [\[CrossRef\]](#)
40. Umbayev, B.; Askarova, S.; Almbayeva, A.; Saliev, T.; Masoud, A.R.; Bulanin, D. Galactose-induced skin aging: The role of oxidative stress. *Oxidative Med. Cell. Longev.* **2020**, *2020*, 7145656. [\[CrossRef\]](#)
41. Cho, K.-H.; Bahuguna, A.; Jeon, C.; Lee, S.H.; Lee, Y.; Baek, S.H.; Yang, C.-E.; Kim, J.-E.; Jayanti, K. Cuban sugarcane wax alcohol supplementation prevents brain and eye damages of zebrafish Exposed to high-cholesterol and high-galactose diet for 30 Weeks: Protection of myelin, cornea, and retina. *Antioxidants* **2025**, *14*, 1453. [\[CrossRef\]](#) [\[PubMed\]](#)
42. Hoste, E.; Haufroid, V.; Deldicque, L.; Balligand, J.L.; Elens, L. Atorvastatin-associated myotoxicity: A toxicokinetic review of pharmacogenetic associations to evaluate the feasibility of precision pharmacotherapy. *Clin. Biochem.* **2024**, *124*, 110707. [\[CrossRef\]](#) [\[PubMed\]](#)
43. Nam, D.-E.; Yun, J.-M.; Kim, D.; Kim, O.-K. Policosanol attenuates cholesterol synthesis via AMPK activation in hypercholesterolemic rats. *J. Med. Food* **2019**, *22*, 1110–1117. [\[CrossRef\]](#) [\[PubMed\]](#)
44. Ng, C.H.; Leung, K.Y.; Huang, Y.; Chen, Z.Y. Policosanol has no antioxidant activity in human low-density lipoprotein but increases excretion of bile acids in hamsters. *J. Agric. Food Chem.* **2005**, *53*, 6289–6293. [\[CrossRef\]](#)
45. Kim, J.-Y.; Kim, S.-M.; Kim, S.-J.; Lee, E.-Y.; Kim, J.-R.; Cho, K.-H. Consumption of policosanols enhances HDL functionality via CETP inhibition and reduces blood pressure and visceral fat in young and middle-aged subjects. *Int. J. Mol. Med.* **2017**, *39*, 889–899. [\[CrossRef\]](#)
46. Imerb, N.; Thonusin, C.; Prachayasakul, W.; Arunsak, B.; Nawara, W.; Ongnok, B.; Aeimlapa, R.; Charoenphandhu, N.; Chattipakorn, N.; Chattipakorn, S.C. D-galactose-induced aging aggravates obesity-induced bone dyshomeostasis. *Sci. Rep.* **2022**, *12*, 8580. [\[CrossRef\]](#)
47. Bajaj, S.; Khan, A. Antioxidants and diabetes. *Indian J. Endocrinol. Metab.* **2012**, *16*, S267–S271. [\[CrossRef\]](#)
48. Koh, K.K.; Sakuma, I.; Quon, M.J. Differential metabolic effects of distinct statins. *Atherosclerosis* **2011**, *215*, 1–8. [\[CrossRef\]](#)
49. Cordiano, R.; Di Gioacchino, M.; Mangifesta, R.; Panzera, C.; Gangemi, S.; Minciullo, P.L. Malondialdehyde as a potential oxidative stress marker for allergy-oriented diseases: An update. *Molecules* **2023**, *28*, 5979. [\[CrossRef\]](#)
50. Bourgonje, A.R.; Abdulle, A.E.; Bourgonje, M.F.; Binnenmars, S.H.; Gordijn, S.J.; Bulthuis, M.L.C.; la Bastide-van Gemert, S.; Kieneker, L.M.; Gansevoort, R.T.; Bakker, S.J.L.; et al. Serum free sulfhydryl status associates with new-onset chronic kidney disease in the general population. *Redox Biol.* **2021**, *48*, 102211. [\[CrossRef\]](#)
51. Hu, M.-L. Measurement of protein thiol groups and glutathione in plasma. *Methods Enzymol.* **1994**, *233*, 380–385. [\[PubMed\]](#)
52. Arora, M.K.; Pandey, S.; Tomar, R.; Sahoo, J.; Kumar, D.; Jangra, A. Therapeutic potential of policosanols in the concurrent management of dyslipidemia and non-alcoholic fatty liver disease. *Future J. Pharm. Sci.* **2022**, *8*, 11. [\[CrossRef\]](#)
53. Ottum, M.S.; Mistry, A.M. Advanced glycation end products: Modifiable environmental factors profoundly mediate insulin resistance. *J. Clin. Biochem. Nutr.* **2015**, *57*, 1–12. [\[CrossRef\]](#) [\[PubMed\]](#)
54. Teratani, T.; Tomita, K.; Suzuki, T.; Oshikawa, T.; Yokoyama, H.; Shimamura, K.; Tominaga, S.; Hiroi, S.; Irie, R.; Okada, Y. A high-cholesterol diet exacerbates liver fibrosis in mice via accumulation of free cholesterol in hepatic stellate cells. *Gastroenterology* **2012**, *142*, 152–164. [\[CrossRef\]](#)
55. Azman, K.F.; Safdar, A.; Zakaria, R. D-galactose-induced liver aging model: Its underlying mechanisms and potential therapeutic interventions. *Exp. Gerontol.* **2021**, *150*, 111372. [\[CrossRef\]](#)
56. Qi, X.F.; Zheng, L.; Lee, K.J.; Kim, D.H.; Kim, C.S.; Cai, D.Q.; Wu, Z.; Qin, J.W.; Yu, Y.H.; Kim, S.K. HMG-CoA reductase inhibitors induce apoptosis of lymphoma cells by promoting ROS generation and regulating Akt, Erk and p38 signals via suppression of mevalonate pathway. *Cell Death Dis.* **2013**, *4*, e518. [\[CrossRef\]](#)
57. Zeng, L.; Lin, L.; Xiao, W.; Li, Y. L-theanine protects rat kidney from D-galactose-induced injury via inhibition of the AGEs/RAGE signaling pathway. *Eur. J. Pharmacol.* **2022**, *927*, 175072. [\[CrossRef\]](#)
58. Yamagishi, S.; Matsui, T. Advanced glycation end products, oxidative stress and diabetic nephropathy. *Oxidative Med. Cell. Longev.* **2010**, *3*, 101–108. [\[CrossRef\]](#)

59. Garavaglia, M.L.; Giustarini, D.; Colombo, G.; Reggiani, F.; Finazzi, S.; Calatroni, M.; Landoni, L.; Portinaro, N.M.; Milzani, A.; Badalamenti, S.; et al. Blood thiol redox state in chronic kidney disease. *Int. J. Mol. Sci.* **2022**, *23*, 2853. [\[CrossRef\]](#)
60. Budni, J.; Pacheco, R.; da Silva, S.; Garcez, M.L.; Mina, F.; Bellettini-Santos, T.; de Medeiros, J.; Voss, B.C.; Steckert, A.V.; Valvassori, S.d.S.; et al. Oral administration of D-galactose induces cognitive impairments and oxidative damage in rats. *Behav. Brain Res.* **2016**, *302*, 35–43. [\[CrossRef\]](#)
61. Qu, Z.; Zhang, J.; Yang, H.; Huo, L.; Gao, J.; Chen, H.; Gao, W. Protective effect of tetrahydropalmatine against d-galactose induced memory impairment in rat. *Physiol. Behav.* **2016**, *154*, 114–125. [\[CrossRef\]](#)
62. D’Cunha, N.M.; Sergi, D.; Lane, M.M.; Naumovski, N.; Gamage, E.; Rajendran, A.; Kouvari, M.; Gauci, S.; Dissanayaka, T.; Marx, W.; et al. The effects of dietary advanced glycation end-products on neurocognitive and mental disorders. *Nutrients* **2022**, *14*, 2421. [\[CrossRef\]](#) [\[PubMed\]](#)
63. Khosla, S.; Farr, J.N.; Tchkonina, T.; Kirkland, J.L. The role of cellular senescence in ageing and endocrine disease. *Nat. Rev. Endocrinol.* **2020**, *16*, 263–275. [\[CrossRef\]](#)
64. Wang, Q.; Zheng, X.-L.; Yang, L.; Shi, F.; Gao, L.-B.; Zhong, Y.-J.; Sun, H.; He, F.; Lin, Y.; Wang, X. Reactive oxygen species-mediated apoptosis contributes to chemosensitization effect of saikosaponins on cisplatin-induced cytotoxicity in cancer cells. *J. Exp. Clin. Cancer Res.* **2010**, *29*, 159. [\[CrossRef\]](#)
65. Yan, M.; Man, S.; Sun, B.; Ma, L.; Guo, L.; Huang, L.; Gao, W. Gut liver brain axis in diseases: The implications for therapeutic interventions. *Signal Transduct. Target. Ther.* **2023**, *8*, 443. [\[CrossRef\]](#) [\[PubMed\]](#)
66. Miranda, A.S.; Cordeiro, T.M.; Dos Santos Lacerda Soares, T.M.; Ferreira, R.N.; Simões e Silva, A.C. Kidney-brain axis inflammatory crosstalk: From bench to bedside. *Clin. Sci.* **2017**, *131*, 1093–1105. [\[CrossRef\]](#) [\[PubMed\]](#)
67. Zhong, L.; Wang, T.; Wang, T.; Chen, H.; Deng, J.; Ye, H.; Li, W.; Ling, S. Characterization of an i.p. D-galactose-induced cataract model in rats. *J. Pharmacol. Toxicol. Methods* **2021**, *107*, 106891. [\[CrossRef\]](#)
68. El-Sayyad, H.I.; Elmansi, A.A.; Bakr, E.H. Hypercholesterolemia-induced ocular disorder: Ameliorating role of phytotherapy. *Nutrition* **2015**, *31*, 1307–1316. [\[CrossRef\]](#)
69. O’Sullivan, S.A.; Velasco-Estevez, M.; Dev, K.K. Demyelination induced by oxidative stress is regulated by sphingosine 1-phosphate receptors. *Glia* **2017**, *65*, 1119–1136. [\[CrossRef\]](#)
70. Cho, K.-H.; Bahuguna, A.; Kim, J.-E.; Lee, Y.; Lee, S.H. Comparative assessment of Beeswax alcohol and coenzyme Q₁₀ (CoQ₁₀) to prevent liver aging, organ damage, and oxidative stress in hyperlipidemic zebrafish exposed to D-galactose: A 12-Week dietary intervention. *Pharmaceuticals* **2024**, *17*, 1250. [\[CrossRef\]](#)
71. Pandey, A.K.; Gupta, A.; Tiwari, M.; Prasad, S.; Pandey, A.N.; Yadav, P.K.; Sharma, A.; Sahu, K.; Asrafuzzaman, S.; Vengayil, D.T.; et al. Impact of stress on female reproductive health disorders: Possible beneficial effects of shatavari (*Asparagus racemosus*). *Biomed. Pharmacother.* **2018**, *103*, 46–49. [\[CrossRef\]](#)
72. Khoshdel, F.; Golmohammadi, M.G.; Dost, M.J.; Najafzade, N.; Salimnejad, R. Impact of caffeic acid on the testicular damages in D-galactose-induced aging model in mice. *Iran. J. Basic Med. Sci.* **2022**, *25*, 1190.
73. Vasyutina, M.; Alieva, A.; Reutova, O.; Bakaleiko, V.; Murashova, L.; Dyachuk, V.; Catapano, A.L.; Baragetti, A.; Magni, P. The zebrafish model system for dyslipidemia and atherosclerosis research: Focus on environmental/exposome factors and genetic mechanisms. *Metab. Clin. Exp.* **2022**, *129*, 155138. [\[CrossRef\]](#)
74. Zang, L.; Maddison, L.A.; Chen, W. Zebrafish as a model for obesity and diabetes. *Front. Cell Dev. Biol.* **2018**, *6*, 91. [\[CrossRef\]](#)
75. Cho, K.-H.; Kim, J.-E.; Lee, M.-S.; Bahuguna, A. Oral supplementation of ozonated sunflower oil augments plasma antioxidant and anti-Inflammatory abilities with enhancement of high-density lipoproteins functionality in rats. *Antioxidants* **2024**, *13*, 529. [\[CrossRef\]](#)
76. OECD. Test No. 203: Fish, Acute Toxicity Testing. In *OECD Guidelines for the Testing of Chemicals*; Section 2; OECD Publishing: Paris, France, 2019.
77. Cho, K.-H.; Kim, J.-E.; Bahuguna, A.; Kang, D.-J. Long-term supplementation of ozonated sunflower oil improves dyslipidemia and hepatic inflammation in hyperlipidemic zebrafish: Suppression of oxidative stress and inflammation against carboxymethyllysine toxicity. *Antioxidants* **2023**, *12*, 1240. [\[CrossRef\]](#)
78. Fischer, A.H.; Jacobson, K.A.; Rose, J.; Zeller, R. Hematoxylin and eosin staining of tissue and cell sections. *Cold Spring Harb. Protoc.* **2008**, 2008, prot4986. [\[CrossRef\]](#)

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.